Your browser is no longer supported. Please, upgrade your browser.
Onconova Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.33 Insider Own0.20% Shs Outstand15.98M Perf Week-16.72%
Market Cap60.40M Forward P/E- EPS next Y-1.05 Insider Trans44.51% Shs Float14.81M Perf Month-28.07%
Income-18.80M PEG- EPS next Q-0.27 Inst Own17.50% Short Float2.35% Perf Quarter-49.43%
Sales0.20M P/S302.02 EPS this Y90.30% Inst Trans39.42% Short Ratio0.17 Perf Half Y-61.12%
Book/sh3.11 P/B0.85 EPS next Y8.50% ROA-43.50% Target Price11.50 Perf Year-45.07%
Cash/sh2.60 P/C1.02 EPS next 5Y- ROE-59.80% 52W Range2.69 - 28.95 Perf YTD-62.22%
Dividend- P/FCF- EPS past 5Y- ROI-403.20% 52W High-90.88% Beta1.72
Dividend %- Quick Ratio8.50 Sales past 5Y-54.20% Gross Margin- 52W Low-1.86% ATR0.21
Employees11 Current Ratio8.50 Sales Q/Q0.00% Oper. Margin- RSI (14)30.17 Volatility9.12% 6.53%
OptionableYes Debt/Eq0.00 EPS Q/Q58.20% Profit Margin- Rel Volume0.25 Prev Close2.89
ShortableYes LT Debt/Eq0.00 EarningsNov 11 AMC Payout- Avg Volume2.02M Price2.64
Recom2.00 SMA20-19.11% SMA50-25.08% SMA200-66.14% Volume496,586 Change-8.65%
May-18-21Initiated Guggenheim Buy $4
Mar-01-18Reiterated H.C. Wainwright Buy $6 → $7.50
Jan-17-18Downgrade Maxim Group Buy → Hold
Oct-09-17Initiated H.C. Wainwright Buy $6
Apr-27-17Initiated Laidlaw Buy $10
Jul-01-15Upgrade Piper Jaffray Neutral → Overweight
May-05-15Initiated H.C. Wainwright Buy $6
Dec-02-21 08:00AM  
Nov-22-21 08:00AM  
Nov-11-21 04:01PM  
Nov-04-21 03:01PM  
Oct-01-21 12:35PM  
Sep-29-21 08:00AM  
Sep-28-21 04:05PM  
Sep-24-21 12:13PM  
Sep-23-21 04:01PM  
Sep-22-21 03:15PM  
Sep-20-21 08:00AM  
Sep-09-21 08:00AM  
Aug-12-21 07:25PM  
Aug-05-21 08:00AM  
Aug-04-21 03:00PM  
Jun-28-21 08:00AM  
Jun-22-21 08:00AM  
Jun-17-21 08:00AM  
Jun-10-21 08:00AM  
Jun-04-21 12:00PM  
Jun-03-21 08:00AM  
Jun-01-21 08:00AM  
May-21-21 08:00AM  
May-20-21 08:32AM  
May-17-21 04:05PM  
May-14-21 10:25AM  
May-10-21 08:00AM  
May-06-21 03:01PM  
Apr-22-21 08:00AM  
Apr-01-21 08:00AM  
Mar-29-21 08:00AM  
Mar-11-21 04:05PM  
Mar-04-21 04:15PM  
Mar-01-21 08:00AM  
Feb-24-21 08:00AM  
Feb-22-21 09:47AM  
Feb-17-21 05:51PM  
Feb-16-21 04:03PM  
Feb-10-21 10:49PM  
Feb-04-21 11:54AM  
Jan-25-21 09:49AM  
Jan-14-21 08:00AM  
Jan-07-21 09:40AM  
Dec-21-20 08:00AM  
Dec-01-20 10:27AM  
Nov-23-20 08:00AM  
Nov-12-20 04:05PM  
Nov-05-20 08:00AM  
Oct-13-20 08:00AM  
Oct-05-20 09:44AM  
Sep-21-20 10:08AM  
Sep-09-20 08:00AM  
Aug-31-20 08:41AM  
Aug-26-20 06:42PM  
Aug-25-20 10:06AM  
Aug-24-20 11:15AM  
Aug-17-20 11:46AM  
Aug-12-20 04:37PM  
Aug-07-20 08:00AM  
Aug-04-20 08:00AM  
Aug-03-20 11:52AM  
Jul-29-20 01:30PM  
Jul-27-20 08:00AM  
Jul-23-20 08:00AM  
Jul-07-20 08:00AM  
Jun-23-20 10:43AM  
Jun-22-20 08:00AM  
Jun-12-20 08:00AM  
Jun-08-20 08:00AM  
May-28-20 09:44AM  
May-18-20 11:33AM  
May-14-20 04:05PM  
May-11-20 08:00AM  
May-07-20 08:00AM  
Apr-27-20 08:00AM  
Apr-07-20 06:40AM  
Apr-02-20 07:00AM  
Mar-24-20 04:05PM  
Mar-18-20 08:00AM  
Mar-13-20 09:46AM  
Mar-02-20 09:54AM  
Feb-21-20 10:12AM  
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OLER ABRAHAM N.SVP CORP DEV & GEN COUNSELNov 19Buy3.161,0003,16018,514Nov 23 09:20 AM
OLER ABRAHAM N.SVP Corp Dev & Gen CounselSep 28Buy4.202,38110,00012,515Sep 29 08:27 AM
Gelder Mark S. MDChief Medical OfficerSep 28Buy4.202,38110,0002,381Sep 29 08:25 AM
Fruchtman Steven MPresident, Chief Executive OffSep 28Buy4.202,38110,00018,130Sep 28 12:34 PM
MARINO JAMES JDirectorSep 28Buy4.205,95224,99821,334Sep 28 12:32 PM
OLER ABRAHAM N.SVP Corp Dev & Gen CounselFeb 16Buy1.0012,00012,000152,000Feb 17 08:57 AM
Guerin Mark PatrickChief Financial OfficerFeb 16Buy1.0015,00015,000145,213Feb 17 08:55 AM
Fruchtman Steven MPresident, Chief Executive OffFeb 16Buy1.0020,00020,000236,226Feb 17 08:48 AM
MARINO JAMES JDirectorFeb 16Buy1.0025,00025,000230,716Feb 17 08:46 AM
Shoemaker Mary TeresaDirectorFeb 16Buy1.0013,00013,00050,735Feb 17 08:45 AM
OLER ABRAHAM N.SVP Corp Dev & Gen CounselDec 11Buy0.3230,0009,600140,000Dec 14 09:00 AM